---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021846"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:29:05.753525+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023

## Summary
- Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.
- BARDA awards contract for pandemic preparedness: initial ~$55M, potential up to $1B.
- GSK opted-in to collaborate on RSV antibodies; profit-sharing from GSK $291.2M in Q3.
- Phase 2 trials for HBV, HDV (SOLSTICE), influenza A (PENINSULA); initial data expected in 2023.
- Strong balance sheet: ~$2.7B cash, investments, and profit-share payments.

## SEC filing metadata
- accession: 0000950170-22-021846
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/0000950170-22-021846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/vir-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021846
- JSON: https://secwatch.observer/filing/0000950170-22-021846.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021846.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000095017022021846/0000950170-22-021846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.